Zomedica Appoints Robert DiMarzo as Executive Vice

ANN ARBOR, Mich., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (TSX-V: ZOM ), a veterinary pharmaceutical and health care solutions company, today announced that Robert W. DiMarzo has joined the company as Executive Vice President of Global Strategy. In this new company position, DiMarzo is responsible for expanding Zomedica’s business outside North America via business development opportunities and globalization strategies for existing pipeline products.

“A proven entrepreneur in the animal health space, Robert’s extensive experience in the United States, Europe, Asia, and Latin America, for industry leaders such as Pfizer Animal Health, complements the qualifications of our talented executive team,” stated Gerald Solensky Jr., Chief Executive Officer at Zomedica. “Given his successful animal health background, Robert is here to help bring our unique pipeline of therapeutics and diagnostics to the global markets.”

DiMarzo comes to Zomedica with more than 25 years of animal health leadership experience in manufacturing, distribution, marketing and sales, and strategic operations for pharmaceutical and diagnostic companies. Prior to joining Zomedica, DiMarzo served as Principal with DiMarzo Business Consulting where he advised business, financial, and government entities on globalization, business development, and growth strategies within the animal health and human biotechnology industries.

Prior to that, DiMarzo was Vice President of Commercial Development and Product Category Management with the global animal health group at Henry Schein. Before that, he was Executive Chairman of the U.S. animal health distributor Ivesco Holdings LLC. Under his leadership, Ivesco transformed into a successful category leader that was acquired in November 2013 by MWI Veterinary Supply, Inc., now a wholly-owned subsidiary of AmerisourceBergen. DiMarzo also served as Executive Vice President of Sales and Marketing for the veterinary diagnostic startup Scandinavian Micro Biodevices, purchased by Zoetis in 2016.

DiMarzo started his animal health career with Elanco, the animal health division of Eli Lilly, followed by 15 years with Pfizer Animal Health (now Zoetis) where he held several director-level and executive leadership positions in Brazil, Italy, and the U.S., leaving the company as President of U.S. Operations. During his tenure, DiMarzo elevated Pfizer’s U.S. Animal Health division to that of a recognized industry leader.

A former U.S. Naval Officer and Peace Corps volunteer, DiMarzo has a Master of Business Administration from Harvard University and Bachelor of Science from Brown University.

About Zomedica With U.S. operations based in Ann Arbor, Michigan, Zomedica is a veterinary pharmaceutical and health care solutions company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. Zomedica is developing a diversified portfolio to include innovative drugs, drug-delivery technologies, diagnostics, and devices. With multiple clinical veterinarians in executive management, it is Zomedica’s mission to give veterinarians the opportunity to lower costs, increase productivity, and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com .

Follow Zomedica

• Email Alerts: http://www.zomedica.com/investor-information/
• LinkedIn: https://www.linkedin.com/company/zomedica
• Facebook: https://www.facebook.com/zomedica/

Reader Advisory Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the release.

Except for statements of historical fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.

Forward-looking information is based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and business plans will yield the expected benefits; availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to future clinical trials, regulatory approvals, safety and efficacy of our products, the use of our product, intellectual property protection and the other risk factors disclosed under our profile on SEDAR at www.sedar.com . Readers are cautioned that this list of risk factors should not be construed as exhaustive.

The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.

Investor Relations Contact Shameze Rampertab, CPA, CA srampertab@zomedica.com +1 647.283.3630 Barry Mire, Renmark Financial Communications Inc. bmire@renmarkfinancial.com +1 416.644.2020 or +1 514.939.3989 Media Contact Andrea Eberle aeberle@zomedica.com +1 734.369.2555